The Global Lipid Nanoparticles (LNPs) CDMO market size is expected to grow at a compound annual growth rate (CAGR) of 13.8% from 2022 to 2030. In recent years, a remarkable advancement in nanoscale drug delivery methods has been made. A novel nano-colloidal system for drug administration has emerged in the form of solid lipid nanoparticles (SLNs). Due to the lipid matrix's biocompatibility, lipid nanoparticles (LNPs) are frequently used in drug delivery. The most promising method for oral delivery is solid lipid nanoparticles (SLN), which have improved solubility, stability, permeability, and bioavailability while posing fewer side effects than standard dose formulations. Increasing clinical demand for small molecules is favouring the business of contract manufacturing service providers.
The most advanced non-viral therapeutically authorised mRNA delivery technologies are lipid nanoparticles (LNPs). The ability of an mRNA vaccine to deliver a therapeutic outcome is related to the capacity of LNPs to provide the nucleic acid intact into cells. For Instance, in 2021, WACKER and CordenPharma signed a development collaboration in the field of Lipid Nanoparticle formulation. The two companies reported that they intend to jointly develop know-how and methods for manufacturing Lipid Nanoparticles (LNPs) to meet the growing market demand.
Major driving factors of the Lipid Nanoparticles (LNPs) CDMO market are the surging medical applications of nanoparticles, increasing investments by key players in lipid nanoparticles to develop promising drug therapies, rising cases of chronic diseases, an increasing aging population, and a growing number of health-conscious people. The rising chronic and infectious disease cases have increased pharmaceutical companies' product manufacturing burden. Hence, biopharma companies started to opt for contract manufacturing services to save time and handle lipid/nanoparticle production operations, which is expected to create business growth opportunities for the market over the forecast years. However, the high cost of outsourced services, lack of necessary infrastructures, need for specialized expertise for nanoparticle production, and complex manufacturing procedures may restrain the market growth during the estimated timeframe.
The Lipid Nanoparticles (LNPs) CDMO market is segmented based on product, the scale of operation, end-users, and region. The product segment comprises mRNA , Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and Others. By scale of operation, the market is classified into preclinical scale operations, clinical scale operations, and commercial-scale operations. The market is grouped into Pharmaceutical Companies, Academic Research Institute, and Diagnostic Laboratories. Pharmaceutical companies are projected to hold a significant market share over the forecast years owing to the high prevalence of chronic diseases and rising innovative drug developments. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
North America is estimated to witness rapid growth in the next few years due to the increasing awareness about the applications of nanoparticles, rising government investments in the R&D of nanoparticle products, and the high prevalence of chronic diseases.
Some of the key players operating in the Lipid Nanoparticles (LNPs) CDMO market are Corden Pharma GmbH, eTheRNA, Curapath (Polypeptide Therapeutic Solutions (PTS)), FUJIFILM Corporation, ST Pharm Co Ltd, Exelead (Merck KGaA) , Avanti Polar Lipids, Inc. (Croda International Plc.), Emergent CDMO, Esco Aster Pte Ltd, Vernal Biosciences, Arranta Bio, Phosphorex Inc, Ardena Holding NV, Curia Global, Inc., Helix Biotech, Polymun Scientific Immunbiologische Forschung GmbH, and Other Prominent Players